DPO-1

DPO-1 is a potent inhibitor of the voltage-gated potassium channel subtype Kv1.5 and a blocker of ultrarapid delayed rectifier potassium current. DPO-1 prevents atrial arrhythmia[1][2].

ChEBI: [[(1S,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]-phenylphosphoryl]benzene is a monoterpenoid.

Blocker of I Kur ultrarapid delayed rectifier potassium current and K V 1.5 channels (IC 50 = 0.31 μ M for rK V 1.5). Displays selectivity for inhibition of I Kur over I to (8-fold), I K1 , I Kr and I Ks (20-fold) in native myocytes and selectivity for rat recombinant K V 1.5 over K V 3.1 (~ 15-fold). Increases action potential duration in atrial but not ventricular myocytes and prevents atrial arrhythmia.

Store at +4°C

[1] Lagrutta A, et al. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63. DOI:10.1124/jpet.106.101162
[2] Stump GL, et al. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther. 2005 Dec;315(3):1362-7. DOI:10.1124/jpet.105.092197